Intersect ENT Appoints David Lehman General Counsel MENLO PARK, Calif., February 22, 2016 – Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat - David Lehman - Document - PDFSEARCH.IO

First Page		Document Content
Intersect ENT Propel mometasone furoate implant Forward-looking statement Otorhinolaryngology Sinusitis Thoratec		Intersect ENT Appoints David Lehman General Counsel MENLO PARK, Calif., February 22, 2016 – Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat Add to Reading List Source URL: propelopens.com Download Document from Source Website File Size: 99,40 KB Share Document on Facebook

	PROPEL® mini (mometasone furoate implant, 370 µg) Instructions For Use CAREFULLY READ ALL INSTRUCTIONS PRIOR TO USE STERILE: STORAGE: DocID: 1suji - View Document
	PROPEL® (mometasone furoate implant, 370 µg) Instructions For Use CAREFULLY READ ALL INSTRUCTIONS PRIOR TO USE STERILE: STORAGE: DocID: 1qyzI - View Document
	Intersect ENT Announces Publication of PROGRESS Study of Steroid Releasing Implant in Patients With Frontal Sinus Disease Results Demonstrate Clinical Benefits of PROPEL mini in Difficult-to-Treat Patient Population MENL DocID: 1pP5m - View Document
	Intersect ENT Announces Completion of Enrollment in RESOLVE II Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis Company Also Announces Publication of Positive Six-Month Results from RESOLVE Clinica DocID: 1okP8 - View Document
	Intersect ENT Recognized for Gender Diversity by Watermark and UC Davis Company Also Recognized in Deloitte’s 2015 Technology Fast 500 MENLO PARK, Calif., November 17, 2015 – Intersect ENT, Inc. (Nasdaq:XENT), a comp DocID: 1oeqx - View Document